Envision Pharma Group appoints Richard Gorman as President, Strategic Consulting

Envision Pharma Group (Envision) has appointed Richard “Rich” Gorman to the role of President, Strategic Consulting and member of the Executive Leadership Team.

Rich is a 30-year veteran of the life sciences industry and a respected leader with a track record of success in pharmaceutical commercialization. He is an experienced head of high-performing teams that build go-to-market strategies to deliver on business development and revenue generation goals.

Rich will be responsible for leading the Strategic Consulting business across Envision’s commercial, medical, and technology sectors. He will lead a team of scientific, medical, and commercial strategists with deep expertise in the life sciences industry while combining its technology and AI platforms to accelerate the business and scientific momentum of clients’ strategies.

Prior to joining Envision, Rich served as Chief Commercial Officer and Global Head of Strategy for Amplity Health. Before that, he held various leadership positions and senior business development roles at Syneos Health. His background includes serving as a CEO for a specialty pharmaceutical company, as well as several positions within the field of contract pharmaceutical development and manufacturing.

Rich shares, “I am delighted to be joining Envision Pharma Group at this pivotal and exciting time. I am honored to have the opportunity to lead this talented team of strategy consultants. Combining their proven capabilities with the Envision technology platform will create a powerful option for manufacturers looking to efficiently bring new science and products to patients.”  

Meg Heim, Chief Executive Officer of Envision Pharma Group states, “We are so excited to have Rich join our team as we continue to accelerate Envision’s business expansion, mission, and commitment to our clients’ needs. Rich’s proven expertise will be critical in partnering with our clients to execute upon their goals, improve performance, and meet their unique business needs with the support of our technology platforms and strategic advisory expertise.”

Close

Every year, Envision Pharma Group holds a Medical Affairs (MA) Round Table meeting to bring together industry leaders and discuss current topics within MA. This year, approximately 15 attendees met in New York City to discuss industry best practices, understand common challenges that often arise – and have the opportunity to network with other industry leaders. The annual meeting helps to focus on, and discuss, important and valuable topics within our industry together. Past topics have included:

Past topic have included:

• Global Alignment in Medical Affairs
• Patient Engagement: Real-World Evidence
• Insights Identification
• Automation & Organizational Efficiencies
• Medical Affairs Metrics
• Thought-Leader Engagement
• Demonstrating the Value of Medical Affairs
• Maximizing Data Roll-Out

The outcomes from this year’s annual round table helped further Envision’s perspective surrounding the current landscape of our industry, and up and coming trends. Along with general industry research, stakeholder interviews, as well as the conversations had with this year’s attendees, the Envision team put together the Medical Affairs 5-year Landscape Analysis. This focuses on the major trends influencing MA and identifies the key findings. Additionally, the team was able to detect some of the major impacts each trend will have upon the industry, based on the information obtained from the research and stakeholder interviews.

Click here for a look at our interactive Landscape Analysis infographic inclusive of the 8 trends and the potential influence they could have on the Medical Affairs industry.

If you would like more information regarding the next Envision Pharma Group Medical Affairs Round Table, please get in touch: EPGRoundtable@Envisionpharmagroup.com

Close

Fuelled by continued growth in its technology solutions unit, Envision Pharma Group is opening a new office in Szeged, Hungary.

Peter Jankovics, Product Development, Technology Solutions said, “It is exciting that we can expand Envision’s presence in Central Europe by opening a modern and stylish office in the center of the beautiful city of Szeged, Hungary. This office will certainly help us to reach more people who could experience the rewarding work environment and culture Envision represents.”

Envision plans to open the doors by the end of year, and in the meantime continues to look for talented individuals interested in working in a global technology environment within the healthcare industry.

For more information on the technology opportunities we have available, contact opportunities-US@EnvisionPharmaGroup.com

Close

Envision has won gold and silver excellence awards for its work in collaboration with Mundipharma at the 10th anniversary of the PM Society Digital Awards.

The Mundipharma account team from Envision headed up to The Brewery, London on the 19th September to attend and await the outcome from the judges.

In recognition for its unique approach to digital creativity, the team scooped one Gold award for ‘Excellence in Congress, Meetings and Events’, along with a Silver for ‘Innovation – Creativity’.

Awards judge and Medical Director Joubert Gama said, “The team were really impressed with this entry, especially in terms of keeping with the theme of the congress which was sustainability. The technology was really well used and the insights gained from different customers were used to guide them for future materials.”

Multichannel Director at Envision Alex Watson added, “Envision Pharma Group are thrilled to have won both of these aspirational PM Society Digital Awards for our work in collaboration with Mundipharma.”

“Bringing physical and tangible interactions to the unbound value of digital communication channels is not only a recipe for communication success for both us and our clients, but more importantly also for healthcare professionals who see real value in having information personalised to their interests and delivered in engaging and memorable ways.”

Now in its 10th year, the PM Society Digital Awards strive to recognise digital effectiveness, creativity and innovation within the healthcare industry – highlighting programmes, tools and campaigns across a range of digital activities.”

There are 15 categories that are all judged over a two-stage process, with many of the judges working within the healthcare industry themselves, who are assisted by creative and digital experts.

Watson noted, “This is the first time Envision have entered the PM Society Digital Awards so to have achieved this accolade is testament to the talents and capabilities of our in-house team. Congratulations to all involved, and thank you Mundipharma for the opportunity.”

Close

Prompted by significant growth, the relocation from its Southport, CT office in August allows for continued company expansion amongst state of the art, modern surroundings. One of the many investments made at this new location is The Lab – an innovation space where teams and clients can immerse themselves and play with the latest technologies enhancing healthcare communications.

Envision Scientific Solutions Global Lead Susanne Clark said, “We’ve moved our Southport office location into this new custom remodeled office area. We are thrilled to be able to continue to grow together in our new space!

“This location provides greater opportunities for our teams to share ideas and collaborate together. The updates we’ve made have created a high tech, connected workspace that will benefit both our existing and future global medical affairs clients. We look forward to welcoming clients into our innovation Lab.”

With a new office opening in Warren, NJ , significant office expansion earlier this year in Horsham and Wilmslow, UK along with recent award successes – 2019 is proving to be an exciting time for the business, clients, and new talent in the medical affairs arena.

Close

Envision has moved its Stirling and Madison offices to a larger combined office location in Warren, NJ. With a collaborative working space and scope for significant team expansion, this new site strengthens and serves as a long-term commitment to East Coast employees and brings Envision even closer to its clients.

Envision Global Business Unit Head Todd Courcy said, “The Warren office is home to staff supporting multiple services, and will continue to be a recruitment hub in the US to support our growth.

“The space showcases state of the art conference rooms, kitchen, offices, work stations, and IT infrastructure. Not to mention the amazing coffee and cappuccino machine!”

With a new office opening in Fairfield, CT, significant office expansion earlier this year in Horsham and Wilmslow, UK along with recent award successes – 2019 is proving to be an exciting time for the business, clients, and new talent in the medical affairs arena.

Close

Envision Pharma Group and the Ectodermal Dysplasia (ED) Society have won the award for “Writing Excellence” at the Communiqué Awards in London’s Park Lane.

The accreditation programme was designed to recognise and commend excellence and best practice in European, international and local healthcare communications – and has praised Envision’s collaboration with the charity, which resulted in a patient information book aimed at children to raise awareness and support around the rare genetic disorder.

“Everybody’s different: An introduction to Ectodermal Dysplasia” was designed for children aged 4+, with and without ED, and allows parents and schools to explain the condition in child-friendly terms. It facilitates empathy and gives children the ideas and motivation to then help their peers.

Speaking at the event was Diana Perry, who is the chief executive of the ED Society, “We are thrilled to have won the Writing Excellence award at the Communiqué Awards tonight in London for our book ‘Everybody’s Different’. We are forever grateful to Envision Pharma Group who helped us to develop the book.”

David Thompson who is the Chief Commercial Officer at Envision, added, “It was a wonderful achievement for the team to be recognised for writing excellence at the industry’s Communiqué awards. To partner with the ED Society and have Diana Perry present to pick up the award was a privilege for us all.

“Most importantly, we maintain real belief and hope that the ‘Everybody’s different’ book aimed at children, can continue to make a real difference for this rare disease patient community.”

Click here for a video and summary from the event hosts, and to see what the judges had to say. To access a copy of the patient information material, click here, and for more information regarding Envision's patient work follow this link.

Close

Envision employees have helped shape a valuable medcomms publication for future specialists called ‘Evidence generation and communication: a guide to getting started in HEOR/market access medical writing’.

This second annual edition of the guide focuses on medical writing roles in the HEOR/market access arenas, and is of interest to anyone who wants to understand more about the business of ensuring access to new medicines and devices for patients.

Martin Bell who is a Senior Writer in Envision’s Curo division, shares his specialist market access/HEOR experience and provides an extensive personal profile on his background and career interests.

“I would say the beauty of my role is that it enables me to work on several therapy areas without becoming too entrenched in any one. The subject matter and project types change from day-to-day. I enjoy the ‘eureka’ satisfaction of persevering with a difficult data set until it finally makes sense!”

Martin adds, “Whether comparing the cost-benefit of treatments or assessing the real-world impact of clinical practices, one must consider the ‘big picture’ and how these factors fit together to best provide evidence for the societal value of a treatment.”

Karen Smoyer who is a Senior Strategy Lead at Envision, also provides insight for the industry publication. “I work in HEOR/market access writing to communicate how treatments developed in clinical trials are used and how well they work among patients in the real world.”

To access the guide from FirstMedCommsJob.com’s website, click here.

Close

Envision Pharma Group is announcing the expansion of its award-winning Envision the Patient team with the appointment of Amanda Boughey as Global Patient Partnership Director from her previous role with Cancer Research UK.

Harnessing over 17 years’ experience in patient-centred healthcare strategy and communications, Amanda will help increase the range of services already offered by Envision in medical affairs and patient partnership – under the leadership of Professor Karen Woolley.

Amanda joins Envision from Cancer Research UK, a world-renowned research and campaign organisation, where she lead multi-stakeholder initiatives comprising clinicians, patients and policy makers – to drive activities focused on the early diagnosis of cancer. Prior to this role, Amanda worked within healthcare agencies delivering global integrated communication programmes in a range of therapy areas, and specialised in patient engagement, behaviour change projects and communications.

In welcoming Amanda, Professor Woolley said, “I believe we’ve passed the tipping point with patient involvement in the pharma industry and are beginning to deeply understand how it will influence and transform the way we work. Evidence of this transformation can already be seen across medical publications, scientific congresses and indeed Medical Affairs teams as they build resources dedicated to patient engagement.

“Our own Envision team recently won the ‘Best Practice’ Award at ISMPP for our research on plain language summaries and the toolkit we co-created with patients, industry, publishers and plain language specialists. It really is an exciting time to be working in this area and I am delighted that Amanda is joining our team to help clients achieve more, bringing years of experience and skills working with pharma, clinicians and patient advocacy groups”.

Amanda added, “Envision has a fascinating, evidence-based approach and access to a broad group of stakeholders within healthcare, so I’m looking forward to working with all of them to amplify the patient voice and ensure patients have access to the very best in scientific research and understanding.”

For further information on Envision the Patient services, please contact: info@envisionthepatient.com

Close

Envision Pharma Group was awarded for outstanding creativity, impact and innovation at the 33rd annual PM Society Awards held at the Grosvenor House in London on February 1, 2019.

The PM Society Awards recognise creativity, impact and innovation across pharmaceutical and healthcare advertising and communications. Their target categories are judged by online healthcare professional surveys, and others by panels drawn from creative agencies and industry.

In addition to winning the Events & Exhibitions Award Gold, Envision also secured a bronze award in the Innovation category.

Global Innovation Director at Envision Vonig Watson said, “Envision Pharma Group are extremely proud to have won both Gold and Bronze at the PM Society Awards for our work in collaboration with Mundipharma.

“Reaching audiences in innovative and engaging ways to offer those individuals real value via tailored experiences has been a real success story for EPG. Gone are the days of forcing content on audiences with the hope of maximum impact and lasting message retention. We understand that audiences choose when and how they engage with content, and in creating unique experiences, we are able to achieve the desired reach and impact. This helps our clients effectively communicate their messages to the right audiences at the right time.

“These awards reflect Envision Pharma Group’s passion in delivering scientific and medical communications effectively. Being selected for this award by an acclaimed judging panel of our peers is recognition of all the hard work that went into achieving this. A huge thank you to the creative team, and to our partners Mundipharma for having the faith and vision to help us bring this to life.”

Click here to access video highlights of this experience, and see our award-winning creative solutions.

Close

Envision is delighted to announce that our ProScribe KK team have moved to new and larger offices in Kojimachi Tokyo, close to the Imperial Palace.

2019 looks set to be an exciting year for ProScribe KK, with its growth in Japan running parallel with the global growth of Envision Pharma Group.

Katsuhisa Arai, General Manager, commented, “The rise of Medical Affairs in Japan has certainly increased client demand for our scientific and technology solutions. With our new offices, we can continue to attract talented and experienced staff to our ProScribe KK team. This will allow us to meet our clients’ increasing needs for ethical and effective solutions.

“Our commitment to our clients is consistent with our company values, including the values of ‘working together’ (relationship 縁) and ‘creating value’ (perform 演). The ProScribe KK team remains most grateful for the trusted and respectful relationships we have with our clients in Japan.”

Close

Envision Pharma Group is pleased to announce the addition of iEnvision Datavision® to the suite of medical affairs support solutions available on the iEnvisionTM platform.

Datavision was originally launched 15 years ago, and has become the industry standard system for global publication management, in use by 19 of the current top 20 pharmaceutical companies.

iEnvision Datavision builds on this industry-wide experience as the new publication management system of choice, with both updated functionality and the wider benefits of the iEnvision platform.

iEnvision Datavision supports industry standards in guideline-compliant medical publication plan management, with functionality supporting enhanced planning, publication development and plan monitoring tasks – improving both strategic alignment and publication management efficiency.

iEnvision Datavision includes industry standard workflows for various publication types, which are adjustable to align with company SOPs. Other iEnvision Datavision features include the most comprehensive peer-reviewed journal and medical congress database available in the industry, together with a new built-in debarment-checking tool.

Envision Technology Solutions’ Platform Lead Russell Traynor said, “iEnvision Datavision, builds on our years of experience with Datavision and medical publications, and is designed to support GPP3 and ICMJE compliant publication planning and development.”

Like other iEnvision solutions, iEnvision Datavision is entirely web-delivered and cloud-based – requiring no installation – and allows platform-level connectivity with both other iEnvision medical affairs solutions and third party systems. The user-friendly and consistent iEnvision user interface includes in-system document editing, reviews and approvals for in-development publications – and presents information from Altmetric and Scopus for published materials.

iEnvision Datavision joins the other available iEnvision solutions supporting content management, internal and externally sponsored research projects, medical education grants, corporate grant making and medical information provision – in a fully connected suite of solutions supporting medical affairs and allied functions.

Close

Envision Pharma Group will be in London for this year’s European Meeting of ISMPP and will be highlighting iEnvision Datavision – a core Solution within our suite of medical affairs support, and the evolution of patient partnership within our medical communications and publications focus.

Held between 22-23 January, the theme for this year is ‘Scientific Communications in a Fast-Paced World: Fighting Fit for the Future’, and sees us hosting roundtable events on patient partnership, plain language summaries and meaningful metrics.

The meeting provides an ideal opportunity for delegates to catch up with all the very latest developments on the iEnvision platform, and to view our co-authored poster with industry and patient partners: ‘Developing plain language summaries of scientific congress abstracts – with patients, for patients: a feasibility study’.

Do stop by our booth to speak to us and get involved in the activities. To find out more, view the ISMPP schedule.

Close